Exhibit








Exhibit 10.2




H.C.Wainwright & Co.


Execution Version
November 5, 2019
STRICTLY CONFIDENTIAL


Caladrius Biosciences, Inc.
110 Allen Road, Second Floor
Basking Ridge, NJ 07920


Attn: David J. Mazzo, Ph.D., President and Chief Executive Officer


Dear Dr. Mazzo:
This letter agreement (this “Agreement”) constitutes the agreement between Caladrius Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement.  The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities.  It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with the transaction.  The Company expressly acknowledges and agrees that Wainwright’s involvement in an Offering is strictly on a reasonable best efforts basis and that the consummation of an Offering will be subject to, among other things, market conditions.  The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company.  At Wainwright’s option and expense, and with Company’s written consent (which consent shall not be unreasonably withheld), Wainwright may engage one or more investment banks or broker-dealers as part of a syndicate in connection with an Offering.
A.    Compensation; Reimbursement.  At the closing of each Offering (each, a “Closing”), the Company shall compensate Wainwright as follows:
		
	1.
	Cash Fee.  The Company shall pay to Wainwright a cash fee, or as to an underwritten Offering an underwriter discount, equal to 7.0% of the aggregate gross proceeds raised in each Offering.


		
	2.
	Expense Allowance.  Out of the proceeds of each Closing, the Company also agrees to pay Wainwright (a) $25,000 for non-accountable expenses; (b) up to $50,000 for reasonable and documented fees and expenses of legal counsel and other out-of-pocket expenses (to be increased to $100,000 in case of a fully marketed public Offering); plus the additional amount payable by the Company pursuant to Paragraph D.3 hereunder and, if applicable, the costs associated with the use of a third-party electronic road show service (such as NetRoadshow); provided, however, 













that such amount in no way limits or impairs the indemnification and contribution provisions of this Agreement.  
		
	3.
	Tail.  In the event that an Offering is not consummated during the Term, Wainwright shall be entitled to compensation under clause (1) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom Wainwright introduced to the Company in the form of a meeting, whether in person or by teleconference, or investors whom Wainwright has  brought over-the-wall during the Term (the “Wainwright Investors”), if such Tail Financing is consummated at any time within the 9-month period following the expiration or termination of this Agreement; provided, however, that the recent investors of the Company who are listed on Exhibit A hereto shall not be deemed Wainwright Investors. A list of such Wainwright Investors shall be provided to the Company as soon as practicable following the termination or expiration of this Agreement. 


		
	4.
	Right of First Refusal.  If Wainwright consummates an Offering during the Term and the Company  decides to raise funds during the period commencing upon the consummation of such Offering and ending six (6) months thereafter by means of a public offering or a private placement or any other capital-raising financing of equity, equity-linked or debt securities using an underwriter or placement agent, then Wainwright (or any affiliate designated by Wainwright) shall have the right to act as lead book-running manager or sole placement agent for such financing.  If Wainwright or one of its affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions for reasonable and customary fees for transactions of similar size and nature; provided, however, that this Paragraph A.4 shall not apply to (i) any financing by the Company whereby the Company does not engage an underwriter, placement agent or other broker-dealer and without the participation of any of Wainwright Investors (for the avoidance of doubt, Wainwright shall receive fees in the amount of 7.0% of the aggregate gross proceeds raised from participating Wainwright Investors), (ii) any financing solely with the participation of non-U.S. institutional investors (other than any offshore investor controlled by a U.S. institutional investor), or (iii) a Strategic Transaction. For the purpose of this Agreement, Strategic Transaction means the issuance of securities in connection with a license, partnership or other strategic transaction; provided that any such issuance shall only be to a person which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.


		
	5.
	Existing Agreements.    Wainwright understands that Company presently has outstanding and ongoing strategic advisory agreements in place as of the date hereof with other entities. The Company represents and warrants that those arrangements are not violative of or contravene this Agreement in any way. Moreover, Wainwright understands and agrees that Company has, as of the date hereof, an “at-the-market” sales agreement with Wainwright as well as an “Equity Purchase Agreement” with Lincoln Park Capital, and that any consideration received for securities sold through those facilities during the Term or the Tail does not constitute an Offering under this Agreement or in any way trigger a fee to Wainwright outside of the existing fees agreed to for sales under the “at-the-market” sales agreement.


B.    Term and Termination of Engagement; Exclusivity.  The term of Wainwright’s exclusive engagement will begin on the date hereof and end three (3) months from the date hereof (the “Term”).  Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, right of first refusal, tail, indemnification and contribution, confidentiality, conflicts, independent contractor and waiver of the 











right to trial by jury will survive any termination or expiration of this Agreement.  Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(f)(2)(D)(ii). The exercise of such right of termination for cause eliminates the Company’s obligations with respect to the provisions relating to the tail fees and right of first refusal. In the event that an Offering pursuant to this Agreement shall not be carried out for any reason whatsoever during the Term, the Company shall be obligated to pay to Wainwright its actual and accountable out-of-pocket expenses related to an Offering (including the fees and disbursements of Wainwright’s legal counsel up to the limit set forth in Paragraph A.3) and, if applicable, for electronic road show service used in connection with an Offering. During the Term: (i) the Company will not, and will not permit its representatives to, other than in coordination with Wainwright, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities and (ii) the Company will not pursue any financing transaction which would be in lieu of an Offering. Additionally, except as set forth hereunder, the Company represents, warrants and covenants that no brokerage or finder’s fees or commissions are or will be payable by the Company or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other third-party with respect to any Offering.
C.    Information; Reliance.  The Company shall furnish, or cause to be furnished, to Wainwright all information reasonably requested by Wainwright for the purpose of rendering services hereunder and conducting due diligence (all such information being the “Information”).  In addition, the Company agrees to make available to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company.  The Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including any documents provided to investors in each Offering (the “Offering Documents”) which shall include any Purchase Agreement (as defined hereunder), and on information available from generally recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; (b) does not assume responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company.  Upon reasonable request, the Company will meet with Wainwright or its representatives to discuss all information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by Wainwright thereof, including any document included or incorporated by reference therein.  At the closing of each Offering, at the request of Wainwright, the Company shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, comfort letters, officers’ and secretary certificates and good standing certificates, all in form and substance reasonably satisfactory to Wainwright and its counsel as is customary for such Offering.  Wainwright shall be a third party beneficiary of any representations, warranties, covenants and closing conditions made by the Company in any Offering Documents, including representations, warranties, covenants and closing conditions made to any investor in an Offering.
D.    Related Agreements.  At each Offering, the Company shall enter into the following additional agreements:
		
	1.
	Underwritten Offering.  If an Offering is an underwritten Offering, the Company and Wainwright shall enter into a customary underwriting agreement in form and substance satisfactory to Wainwright and its counsel.


		
	2.
	Best Efforts Offering.  If an Offering is on a best efforts basis, the sale of Securities to the investors in the Offering will be evidenced by a purchase agreement (“Purchase Agreement”) between the Company and such investors in a form reasonably 













satisfactory to the Company and Wainwright.  Wainwright shall be a third party beneficiary with respect to the representations, warranties and covenants included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquiries from prospective investors.
		
	3.
	Escrow, Settlement and Closing.  If each Offering is not settled via delivery versus payment (“DVP”), the Company and Wainwright shall enter into an escrow agreement with a third party escrow agent pursuant to which Wainwright’s compensation and expenses shall be paid from the gross proceeds of the Securities sold.  If the Offering is settled in whole or in part via DVP, Wainwright shall arrange for its clearing agent to provide the funds to facilitate such settlement. The Company shall pay Wainwright closing costs, which shall also include the reimbursement of the out-of-pocket cost of the escrow agent or clearing agent, as applicable, which closing costs shall not exceed $10,000.


		
	4.
	FINRA Amendments.  Notwithstanding anything herein to the contrary, in the event that Wainwright determines that any of the terms provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall agree to amend this Agreement (or include such revisions in the final underwriting agreement) in writing upon the request of Wainwright to comply with any such rules; provided that any such amendments shall not provide for terms that are less favorable to the Company than are reflected in this Agreement.


E.    Confidentiality.  In the event of the consummation or public announcement of any Offering, Wainwright shall have the right to disclose its participation in such Offering, including, without limitation, the Offering at its cost of “tombstone” advertisements in financial and other newspapers and journals.
F.    Indemnity.
		
	1.
	In connection with the Company’s engagement of Wainwright hereunder, the Company hereby agrees to indemnify and hold harmless Wainwright and its affiliates, and the respective controlling persons, directors, officers, members, shareholders, agents and employees of any of the foregoing (collectively the “Indemnified Persons”), from and against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including the reasonable fees and expenses of counsel), as incurred, whether or not the Company is a party thereto (collectively a “Claim”), that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company’s engagement of Wainwright, or (B) otherwise relate to or arise out of Wainwright’s activities on the Company’s behalf under Wainwright’s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable fees and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified Person is a party.  The Company will not, however, be responsible for any Claim that is finally judicially determined to have resulted from the gross negligence or willful misconduct of any person seeking indemnification for such Claim.  The Company further agrees that no Indemnified Person shall have any 













liability to the Company for or in connection with the Company’s engagement of Wainwright except for any Claim incurred by the Company as a result of such Indemnified Person’s gross negligence or willful misconduct.
		
	2.
	The Company further agrees that it will not, without the prior written consent of Wainwright, settle, compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.


		
	3.
	Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses.  If the Company is requested by such Indemnified Person, the Company will assume the defense of such Claim, including the employment of counsel for such Indemnified Person and the payment of the fees and expenses of such counsel, provided, however, that such counsel shall be satisfactory to the Indemnified Person and provided further that if the legal counsel to such Indemnified Person reasonably determines that the use of counsel chosen by the Company to represent the Indemnified Person would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it or other Indemnified Persons different from or in addition to those available to the Company, such Indemnified Person will employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. If such Indemnified Person does not request that the Company assume the defense of such Claim, such Indemnified Person will employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and all amounts paid as a result of such Claim or the compromise or settlement thereof.  In addition, with respect to any Claim in which the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.


		
	4.
	The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then (whether or not Wainwright is the Indemnified Person), the Company and Wainwright shall contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and Wainwright on the other, in connection with Wainwright’s engagement referred to above, subject to the limitation that in no event shall the amount of Wainwright’s contribution to such 













Claim exceed the amount of fees actually received by Wainwright from the Company pursuant to Wainwright’s engagement.  The Company hereby agrees that the relative benefits to the Company, on the one hand, and Wainwright on the other, with respect to Wainwright’s engagement shall be deemed to be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the applicable Offering (whether or not consummated) for which Wainwright is engaged to render services bears to (b) the fee paid or proposed to be paid to Wainwright in connection with such engagement.
		
	5.
	The Company’s indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Person may have at law or at equity and (b) shall be effective whether or not the Company is at fault in any way.


G.    Limitation of Engagement to the Company.  The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company’s engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), employees or agents.  Unless otherwise expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement.  The Company acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright’s engagement is intended solely for the benefit and use of the Company’s management and directors in considering a possible Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose.  Wainwright shall not have the authority to make any commitment binding on the Company.  The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.
H.    Limitation of Wainwright’s Liability to the Company.  Wainwright and the Company further agree that neither Wainwright nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Wainwright and that are finally judicially determined to have resulted primarily from the gross negligence, fraud or willful misconduct of Wainwright.
I.    Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein.  Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York.  The parties hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York.  The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New 











York.  In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company, arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the Company the costs and expenses incurred in connection therewith, including its reasonable attorneys’ fees.  Any rights to trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company.  
J.    Notices.  All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery, fax or e-mail, if sent to Wainwright, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, e-mail:  dmazzo@caladrius.com, Attention:  Chief Executive Officer.  Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery shall be deemed received on the date of the relevant written record of receipt, notices delivered by fax shall be deemed received as of the date and time printed thereon by the fax machine and notices sent by e-mail shall be deemed received as of the date and time they were sent.
K.    Conflicts.  The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company.  Wainwright shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated transaction.
L.    Anti-Money Laundering.  To help the United States government fight the funding of terrorism and money laundering, the federal laws of the United States require all financial institutions to obtain, verify and record information that identifies each person with whom they do business.  This means Wainwright must ask the Company for certain identifying information, including a government-issued identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers appropriate to verify the Company’s identity, such as certified articles of incorporation, a government-issued business license, a partnership agreement or a trust instrument.
M.    Miscellaneous.  The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound.  This Agreement shall not be modified or amended except in writing signed by Wainwright and the Company.  This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company and their respective assigns, successors, and legal representatives.  This Agreement constitutes the entire agreement of Wainwright and the Company with respect to the subject matter hereof and supersedes any prior agreements with respect to the subject matter hereof.  If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect.  This Agreement may be executed in counterparts (including facsimile or electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.
*********************













In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:  /s/ Edward D. Silvera
Name: Edward D. Silvera
Title: Chief Operating Officer
Date: 11/5/2019






Accepted and Agreed:
Caladrius Biosciences, Inc.
By:  /s/ David J. Mazzo, PhD
Name: David J. Mazzo, PhD
Title: President & CEO

















Exhibit A
Company’s Investors not Subject to Tail






		
	•
	Sanford Health


		
	•
	Mark Pu (China)


		
	•
	IEA Private Investments (China)


		
	•
	Jerilyn Holdings Limited (China)


		
	•
	Union Clinic Limited (China)


		
	•
	Mark Pritzker and affiliated companies, including TJP Capital and GPP Opportunity Fund


		
	•
	Lincoln Park Capital


		
	•
	Jesse Greenfield and affiliates


		
	•
	MAZ Partners



















H.C.Wainwright & Co.






Execution Version


March 11, 2020


STRICTLY CONFIDENTIAL


Caladrius Biosciences, Inc.
110 Allen Road, Second Floor
Basking Ridge, NJ 07920


Attn: David J. Mazzo, Ph.D., President and Chief Executive Officer


Dear Dr. Mazzo:
    
Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of November 5, 2019, by and between Caladrius Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”).  Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement. The parties have agreed to amend the terms of the Engagement Agreement on the terms set forth herein.  


The first sentence of Section B. of the Engagement Agreement shall be amended and restated in its entirety to read as follows: 


“The term of Wainwright’s exclusive engagement will begin on the date hereof and end on April 1, 2020 (the “Term”).”


Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this amendment and shall not be in any way changed, modified or superseded except as set forth herein.


This amendment may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.






[Remainder of page intentionally left blank]






















430 Park Avenue  |  New York, New York 10022  |  212.356.0500 
Security services provided by H.C. Wainwright & Co., LLC  |  Member: FINRA/SIPC













IN WITNESS WHEREOF, this amendment is executed as of the date first set forth above.


    
Very truly yours,


H.C. WAINWRIGHT & CO., LLC




By /s/ Edward D. Silvera
     Name: Edward D. Silvera
     Title: Chief Operating Officer




Accepted and Agreed:


Caladrius Biosciences, Inc.




By  /s/ Joseph Talamo
     Name:  Joseph Talamo
     Title:  Chief Financial Officer




[Signature Page to CLBS Engagement Agreement Amendment]



















H.C.Wainwright & Co.






Execution Version


April 23, 2020


STRICTLY CONFIDENTIAL


Caladrius Biosciences, Inc.
110 Allen Road, Second Floor
Basking Ridge, NJ 07920


Attn: David J. Mazzo, Ph.D., President and Chief Executive Officer


Dear Dr. Mazzo:
    
Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of November 5, 2019, as amended, by and between Caladrius Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”).  Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement. The parties have agreed to amend the terms of the Engagement Agreement on the terms set forth herein.  


The first sentence of Section B. of the Engagement Agreement shall be amended and restated in its entirety to read as follows: 


“The term of Wainwright’s exclusive engagement will begin on the date hereof and end on May 29, 2020 (the “Term”).”


Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this amendment and shall not be in any way changed, modified or superseded except as set forth herein.


This amendment may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.


[Remainder of page intentionally left blank]






















430 Park Avenue  |  New York, New York 10022  |  212.356.0500 
Security services provided by H.C. Wainwright & Co., LLC  |  Member: FINRA/SIPC











IN WITNESS WHEREOF, this amendment is executed as of the date first set forth above.


    
Very truly yours,


H.C. WAINWRIGHT & CO., LLC




By /s/ Mark W. Viklund
     Name: Mark W. Viklund
     Title: Chief Executive Officer




Accepted and Agreed:


Caladrius Biosciences, Inc.




By /s/ David J. Mazzo, PhD
     Name: David J. Mazzo, PhD
     Title: President & CEO




[Signature Page to CLBS Engagement Agreement Amendment]





















H.C.Wainwright & Co.






Execution Version


May 25, 2020






STRICTLY CONFIDENTIAL


Caladrius Biosciences, Inc.
110 Allen Road, Second Floor
Basking Ridge, NJ 07920


Attn: David J. Mazzo, Ph.D., President and Chief Executive Officer


Dear Dr. Mazzo:
    
Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of November 5, 2019, as amended, by and between Caladrius Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”).  Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement. The parties have agreed to amend the terms of the Engagement Agreement on the terms set forth herein.  


The first sentence of Section B. of the Engagement Agreement shall be amended and restated in its entirety to read as follows: 


“The term of Wainwright’s exclusive engagement will begin on the date hereof and end on June 30, 2020 (the “Term”).”


Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this amendment and shall not be in any way changed, modified or superseded except as set forth herein.


This amendment may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.


[Remainder of page intentionally left blank]




















430 Park Avenue  |  New York, New York 10022  |  212.356.0500 
Security services provided by H.C. Wainwright & Co., LLC  |  Member: FINRA/SIPC



















IN WITNESS WHEREOF, this amendment is executed as of the date first set forth above.


    
Very truly yours,


H.C. WAINWRIGHT & CO., LLC


By /s/ Mark W. Viklund
     Name: Mark W. Viklund
     Title: Chief Executive Officer




Accepted and Agreed:


Caladrius Biosciences, Inc.




By  /s/ Joseph Talamo
     Name:  Joseph Talamo
     Title:  Chief Financial Officer




[Signature Page to CLBS Engagement Agreement Amendment]